<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0002089237</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001778016</issuerCik>
      <issuerName>NovaBridge Biosciences</issuerName>
      <secFileNumber>001-39173</secFileNumber>
      <issuerAddress>
        <com:street1>SUITE 400, 2440 RESEARCH BLVD</com:street1>
        <com:city>ROCKVILLE</com:city>
        <com:stateOrCountry>MD</com:stateOrCountry>
        <com:zipCode>20850</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>(240) 745 6330</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Dennis Phillip Andrew</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>CHIEF MEDICAL OFFICER </relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Citigroup Global Markets, Inc.</name>
        <address>
          <com:street1>390 Greenwich St.</com:street1>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10013</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>3431</noOfUnitsSold>
      <aggregateMarketValue>14501.46</aggregateMarketValue>
      <noOfUnitsOutstanding>115270000</noOfUnitsOutstanding>
      <approxSaleDate>12/18/2025</approxSaleDate>
      <securitiesExchangeName>NASDAQ</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>12/17/2025</acquiredDate>
      <natureOfAcquisitionTransaction>Restricted Stock Units Vesting</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>NovaBridge Biosciences</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>10302</amountOfSecuritiesAcquired>
      <paymentDate>12/18/2025</paymentDate>
      <natureOfPayment>Compensation</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <securitiesSoldInPast3Months>
      <sellerDetails>
        <name>Dennis Phillip Andrew</name>
        <address>
          <com:street1>SUITE 400, 2440 RESEARCH BLVD</com:street1>
          <com:city>Rockville</com:city>
          <com:stateOrCountry>MD</com:stateOrCountry>
          <com:zipCode>20850</com:zipCode>
        </address>
      </sellerDetails>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <saleDate>10/01/2025</saleDate>
      <amountOfSecuritiesSold>2986</amountOfSecuritiesSold>
      <grossProceeds>11558.51</grossProceeds>
    </securitiesSoldInPast3Months>
    <remarks>Shares to be sold were from the vesting of the restricted stock units to cover tax obligations. These came from the RSU 2024 incentive plan.</remarks>
    <noticeSignature>
      <noticeDate>12/18/2025</noticeDate>
      <signature>CONFORMED SIGNATURE ON FILE</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
